

Primary Immunodeficiency Therapeutics Market Size, Trends, Analysis, and Outlook By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Others), By Product (Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, Others), by Region, Country, Segment, and Companies, 2024-2030

https://marketpublishers.com/r/PA5FE920DAD7EN.html

Date: March 2024

Pages: 190

Price: US\$ 3,980.00 (Single User License)

ID: PA5FE920DAD7EN

Abstracts

The global Primary Immunodeficiency Therapeutics market size is poised to register 7.55% growth (CAGR) from 2024 to 2030, presenting significant growth prospects for companies operating in the industry. The industry study analyzes the global Primary Immunodeficiency Therapeutics market By Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Others), By Product (Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, Others).

The future of primary immunodeficiency therapeutics is driven by advances in biotechnology, immunology, and gene therapy aimed at addressing the underlying immune system deficiencies in patients with PIDs. Key trends include the development of targeted biologic therapies, such as immunoglobulin replacement therapy, cytokine therapy, and hematopoietic stem cell transplantation, to restore immune function and prevent recurrent infections in individuals with PIDs. Additionally, there's increasing interest in novel approaches, such as gene therapy and gene editing technologies, to correct genetic mutations responsible for specific forms of PID, offering the potential for curative treatments. Moreover, advancements in personalized medicine and precision



therapeutics are leading to tailored treatment regimens based on individual patient characteristics and disease profiles, improving therapeutic efficacy and patient outcomes..

Primary Immunodeficiency Therapeutics Market Drivers, Trends, Opportunities, and Growth Opportunities

This comprehensive study discusses the latest trends and the most pressing challenges for industry players and investors. The Primary Immunodeficiency Therapeutics market research analyses the global market trends, key drivers, challenges, and opportunities in the industry. In addition, the latest Future of Primary Immunodeficiency Therapeutics survey report provides the market size outlook across types, applications, and other segments across the world and regions. It provides data-driven insights and actionable recommendations for companies in the Primary Immunodeficiency Therapeutics industry.

Key market trends defining the global Primary Immunodeficiency Therapeutics demand in 2024 and Beyond

The industry continues to remain an attractive hub for opportunities for both domestic and global vendors. As the market evolves, factors such as emerging market dynamics, demand from end-user sectors, a growing patient base, changes in consumption patterns, and widening distribution channels continue to play a major role.

Primary Immunodeficiency Therapeutics Market Segmentation- Industry Share, Market Size, and Outlook to 2030

The Primary Immunodeficiency Therapeutics industry comprises a wide range of segments and sub-segments. The rising demand for these product types and applications is supporting companies to increase their investment levels across niche segments. Accordingly, leading companies plan to generate a large share of their future revenue growth from expansion into these niche segments. The report presents the market size outlook across segments to support Primary Immunodeficiency Therapeutics companies scaling up production in these sub-segments with a focus on expanding into emerging countries.

Key strategies adopted by companies within the Primary Immunodeficiency Therapeutics industry



Leading Primary Immunodeficiency Therapeutics companies are boosting investments to capitalize on untapped potential and future possibilities across niche market segments and surging demand conditions in key regions. Further, companies are leveraging advanced technologies to unlock opportunities and achieve operational excellence. The report provides key strategies opted for by the top 10 Primary Immunodeficiency Therapeutics companies.

Primary Immunodeficiency Therapeutics Market Study- Strategic Analysis Review

The Primary Immunodeficiency Therapeutics market research report dives deep into the qualitative factors shaping the market, empowering you to make informed decisions-

Industry Dynamics: Porter's Five Forces analysis to understand bargaining power, competitive rivalry, and threats that impact long-term strategy formulation.

Strategic Insights: Provides valuable perspectives on key players and their approaches based on comprehensive strategy analysis.

Internal Strengths and Weaknesses: Develop targeted strategies to leverage strengths, address weaknesses, and capitalize on market opportunities.

Future Possibilities: Prepare for diverse outcomes with in-depth scenario analysis. Explore potential market disruptions, technology advancements, and economic changes.

Primary Immunodeficiency Therapeutics Market Size Outlook- Historic and Forecast Revenue in Three Cases

The Primary Immunodeficiency Therapeutics industry report provides a detailed analysis and outlook of revenue generated by companies from 2018 to 2023. Further, with actual data for 2023, the report forecasts the market size outlook from 2024 to 2030 in three case scenarios- low case, reference case, and high case scenarios.

Primary Immunodeficiency Therapeutics Country Analysis and Revenue Outlook to 2030

The report analyses 22 countries worldwide including the key driving forces and market



size outlook from 2021 to 2030. In addition, region analysis across Asia Pacific, Europe, the Middle East, Africa, North America, and South America is included in the study. For each of the six regions, the market size outlook by segments is forecast for 2030.

North America Primary Immunodeficiency Therapeutics Market Size Outlook-Companies plan for focused investments in a changing environment

The US continues to remain the market leader in North America, driven by a large consumer base, the presence of well-established providers, and a strong end-user industry demand. Leading companies focus on new product launches in the changing environment. The US economy is expected to grow in 2024 (around 2.2% growth in 2024), potentially driving demand for various Primary Immunodeficiency Therapeutics market segments. Similarly, Strong end-user demand is encouraging Canadian Primary Immunodeficiency Therapeutics companies to invest in niche segments. Further, as Mexico continues to strengthen its trade relations and invest in technological advancements, the Mexico Primary Immunodeficiency Therapeutics market is expected to experience significant expansion, offering lucrative opportunities for both domestic and international stakeholders.

Europe Primary Immunodeficiency Therapeutics Market Size Outlook-Companies investing in assessing consumers, categories, competitors, and capabilities

The German industry remains the major market for companies in the European Primary Immunodeficiency Therapeutics industry with consumers in Germany, France, the UK, Spain, Italy, and others anticipated to register a steady demand throughout the forecast period, driving the overall market prospects. In addition, the proactive approach of businesses in identifying and leveraging new growth prospects positions the European Primary Immunodeficiency Therapeutics market for an upward trajectory, fostering both domestic and international interest. Leading brands operating in the industry are emphasizing effective marketing strategies, innovative product offerings, and a keen understanding of consumer preferences.

Asia Pacific Primary Immunodeficiency Therapeutics Market Size Outlook- an attractive hub for opportunities for both local and global companies

The increasing prevalence of indications, robust healthcare expenditure, and increasing investments in healthcare infrastructure drive the demand for Primary Immunodeficiency Therapeutics in Asia Pacific. In particular, China, India, and South East Asian Primary Immunodeficiency Therapeutics markets present a compelling outlook for 2030, acting



as a magnet for both domestic and multinational manufacturers seeking growth opportunities. Similarly, with a burgeoning population and a rising middle class, India offers a vast consumer market. Japanese and Korean companies are quickly aligning their strategies to navigate changes, explore new markets, and enhance their competitive edge. Our report utilizes in-depth interviews with industry experts and comprehensive data analysis to provide a comprehensive outlook of 6 major markets in the region.

Latin America Primary Immunodeficiency Therapeutics Market Size Outlook- Continued urbanization and rising income levels

Rising income levels contribute to greater purchasing power among consumers, spurring consumption and creating opportunities for market expansion. Continued urbanization and rising income levels are expected to sustainably drive consumption growth in the medium to long term.

Middle East and Africa Primary Immunodeficiency Therapeutics Market Size Outlookcontinues its upward trajectory across segments

Robust demand from Middle Eastern countries including Saudi Arabia, the UAE, Qatar, Kuwait, and other GCC countries supports the overall Middle East Primary Immunodeficiency Therapeutics market potential. Fueled by increasing healthcare expenditure of individuals, growing population, and high prevalence across a few markets drives the demand for Primary Immunodeficiency Therapeutics.

Primary Immunodeficiency Therapeutics Market Company Profiles

The global Primary Immunodeficiency Therapeutics market is characterized by intense competitive conditions with leading companies opting for aggressive marketing to gain market shares. The report presents business descriptions, SWOT analysis, growth strategies, and financial profiles. Leading companies included in the study are Baxter international Inc, Bio Products Laboratory Ltd, Biotest AG, CSL Ltd, Grifols S.A, Kedrion Biopharma Inc, LFB group, Lupin Ltd Pharmaceuticals, Octapharma AG, Takeda Pharmaceutical Company Ltd.

Recent Primary Immunodeficiency Therapeutics Market Developments

The global Primary Immunodeficiency Therapeutics market study presents recent market news and developments including new product launches, mergers, acquisitions,



expansions, product approvals, and other updates in the industry.

Primary Immunodeficiency Therapeutics Market Report Scope

Parameters: Revenue, Volume Price

Study Period: 2023 (Base Year); 2018- 2023 (Historic Period); 2024- 2030 (Forecast

Period)

Currency: USD; (Upon request, can be provided in Euro, JPY, GBP, and other Local

Currency)

Qualitative Analysis

Pricing Analysis

Value Chain Analysis

SWOT Profile

Market Dynamics- Trends, Drivers, Challenges

Porter's Five Forces Analysis

Macroeconomic Impact Analysis

Case Scenarios- Low, Base, High

Market Segmentation:

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display



Color Ultrasound

Color Oltrasourid		
B/W Ultrasound		
By Portability		
Trolley or Cart-Based Ultrasound Systems		
Compact/Handheld Ultrasound Systems		
Point-of-Pare (PoC) Ultrasound Systems		
By Application		
Radiology or General Imaging		
Obstetrics or Gynecology		
Cardiology		
Urology		
Vascular		
Orthopedic and Musculoskeletal		
Pain Management		
Others		
By End-User		
Hospitals		
Surgical Centers and Diagnostic Centers		
Maternity Centers		

Ambulatory Care Centers



Research and Academia

Others		
Geographical Segmentation:		
North America (3 markets)		
Europe (6 markets)		
Asia Pacific (6 markets)		
Latin America (3 markets)		
Middle East Africa (5 markets)		
Companies		
Baxter international Inc		
Bio Products Laboratory Ltd		
Biotest AG		
CSL Ltd		
Grifols S.A		
Kedrion Biopharma Inc		
LFB group		
Lupin Ltd Pharmaceuticals		
Octapharma AG		
Takeda Pharmaceutical Company Ltd		

Primary Immunodeficiency Therapeutics Market Size, Trends, Analysis, and Outlook By Disease (Antibody Deficien...



Formats Available: Excel, PDF, and PPT



Contents

1. EXECUTIVE SUMMARY

- 1.1 Primary Immunodeficiency Therapeutics Market Overview and Key Findings, 2024
- 1.2 Primary Immunodeficiency Therapeutics Market Size and Growth Outlook, 2021-2030
- 1.3 Primary Immunodeficiency Therapeutics Market Growth Opportunities to 2030
- 1.4 Key Primary Immunodeficiency Therapeutics Market Trends and Challenges
 - 1.4.1 Primary Immunodeficiency Therapeutics Market Drivers and Trends
- 1.4.2 Primary Immunodeficiency Therapeutics Market Challenges
- 1.5 Competitive Landscape and Key Players
- 1.6 Competitive Analysis- Growth Strategies Adopted by Leading Primary Immunodeficiency Therapeutics Companies

2. PRIMARY IMMUNODEFICIENCY THERAPEUTICS MARKET SIZE OUTLOOK TO 2030

- 2.1 Primary Immunodeficiency Therapeutics Market Size Outlook, USD Million, 2021-2030
- 2.2 Primary Immunodeficiency Therapeutics Incremental Market Growth Outlook, %, 2021- 2030
- 2.3 Segment Snapshot, 2024

3. PRIMARY IMMUNODEFICIENCY THERAPEUTICS MARKET- STRATEGIC ANALYSIS REVIEW

- 3.1 Porter's Five Forces Analysis
- * Threat of New Entrants
- * Threat of Substitutes
- * Intensity of Competitive Rivalry
- * Bargaining Power of Buyers
- * Bargaining Power of Suppliers
- 3.2 Value Chain Analysis
- 3.3 SWOT Analysis

4. PRIMARY IMMUNODEFICIENCY THERAPEUTICS MARKET SEGMENTATION ANALYSIS AND OUTLOOK



- 4.1 Market Segmentation and Scope
- 4.2 Market Breakdown by Type, Application, and Other Segments, 2021-2030

By Type

Stationary 3D and 4D Ultrasound Devices

Portable 3D and 4D Ultrasound Devices

By Display

Color Ultrasound

B/W Ultrasound

By Portability

Trolley or Cart-Based Ultrasound Systems

Compact/Handheld Ultrasound Systems

Point-of-Pare (PoC) Ultrasound Systems

By Application

Radiology or General Imaging

Obstetrics or Gynecology

Cardiology

Urology

Vascular

Orthopedic and Musculoskeletal

Pain Management

Others

By End-User

Hospitals

Surgical Centers and Diagnostic Centers

Maternity Centers

Ambulatory Care Centers

Research and Academia

Others

- 4.3 Growth Prospects and Niche Opportunities, 2023-2030
- 4.4 Regional comparison of Market Growth, CAGR, 2023-2030

5. REGION-WISE MARKET OUTLOOK TO 2030

- 5.1 Key Findings for Asia Pacific Primary Immunodeficiency Therapeutics Market, 2025
- 5.2 Asia Pacific Primary Immunodeficiency Therapeutics Market Size Outlook by Type, 2021- 2030
- 5.3 Asia Pacific Primary Immunodeficiency Therapeutics Market Size Outlook by Application, 2021- 2030
- 5.4 Key Findings for Europe Primary Immunodeficiency Therapeutics Market, 2025



- 5.5 Europe Primary Immunodeficiency Therapeutics Market Size Outlook by Type, 2021- 2030
- 5.6 Europe Primary Immunodeficiency Therapeutics Market Size Outlook by Application, 2021- 2030
- 5.7 Key Findings for North America Primary Immunodeficiency Therapeutics Market, 2025
- 5.8 North America Primary Immunodeficiency Therapeutics Market Size Outlook by Type, 2021- 2030
- 5.9 North America Primary Immunodeficiency Therapeutics Market Size Outlook by Application, 2021- 2030
- 5.10 Key Findings for South America Primary Immunodeficiency Therapeutics Market, 2025
- 5.11 South America Pacific Primary Immunodeficiency Therapeutics Market Size Outlook by Type, 2021- 2030
- 5.12 South America Primary Immunodeficiency Therapeutics Market Size Outlook by Application, 2021- 2030
- 5.13 Key Findings for Middle East and Africa Primary Immunodeficiency Therapeutics Market, 2025
- 5.14 Middle East Africa Primary Immunodeficiency Therapeutics Market Size Outlook by Type, 2021- 2030
- 5.15 Middle East Africa Primary Immunodeficiency Therapeutics Market Size Outlook by Application, 2021- 2030

6. COUNTRY-WISE MARKET SIZE OUTLOOK TO 2030

- 6.1 US Primary Immunodeficiency Therapeutics Market Size Outlook and Revenue Growth Forecasts
- 6.2 US Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.3 Canada Market Size Outlook and Revenue Growth Forecasts
- 6.4 Canada Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.6 Mexico Market Size Outlook and Revenue Growth Forecasts
- 6.6 Mexico Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.7 Germany Market Size Outlook and Revenue Growth Forecasts
- 6.8 Germany Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.9 France Market Size Outlook and Revenue Growth Forecasts
- 6.10 France Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.11 UK Market Size Outlook and Revenue Growth Forecasts
- 6.12 UK Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities



- 6.13 Spain Market Size Outlook and Revenue Growth Forecasts
- 6.14 Spain Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.16 Italy Market Size Outlook and Revenue Growth Forecasts
- 6.16 Italy Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.17 Rest of Europe Market Size Outlook and Revenue Growth Forecasts
- 6.18 Rest of Europe Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.19 China Market Size Outlook and Revenue Growth Forecasts
- 6.20 China Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.21 India Market Size Outlook and Revenue Growth Forecasts
- 6.22 India Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.23 Japan Market Size Outlook and Revenue Growth Forecasts
- 6.24 Japan Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.26 South Korea Market Size Outlook and Revenue Growth Forecasts
- 6.26 South Korea Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.27 Australia Market Size Outlook and Revenue Growth Forecasts
- 6.28 Australia Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.29 South East Asia Market Size Outlook and Revenue Growth Forecasts
- 6.30 South East Asia Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.31 Rest of Asia Pacific Market Size Outlook and Revenue Growth Forecasts
- 6.32 Rest of Asia Pacific Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.33 Brazil Market Size Outlook and Revenue Growth Forecasts
- 6.34 Brazil Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.36 Argentina Market Size Outlook and Revenue Growth Forecasts
- 6.36 Argentina Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.37 Rest of South America Market Size Outlook and Revenue Growth Forecasts
- 6.38 Rest of South America Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.39 Middle East Market Size Outlook and Revenue Growth Forecasts
- 6.40 Middle East Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities
- 6.41 Africa Market Size Outlook and Revenue Growth Forecasts
- 6.42 Africa Primary Immunodeficiency Therapeutics Industry Drivers and Opportunities



7. PRIMARY IMMUNODEFICIENCY THERAPEUTICS MARKET OUTLOOK ACROSS SCENARIOS

- 7.1 Low Growth Case
- 7.2 Reference Growth Case
- 7.3 High Growth Case

8. PRIMARY IMMUNODEFICIENCY THERAPEUTICS COMPANY PROFILES

- 8.1 Profiles of Leading Primary Immunodeficiency Therapeutics Companies in the Market
- 8.2 Business Descriptions, SWOT Analysis, and Growth Strategies
- 8.3 Financial Performance and Key Metrics

Baxter international Inc

Bio Products Laboratory Ltd

Biotest AG

CSL Ltd

Grifols S.A

Kedrion Biopharma Inc

LFB group

Lupin Ltd Pharmaceuticals

Octapharma AG

Takeda Pharmaceutical Company Ltd

9. APPENDIX

- 9.1 Scope of the Report
- 9.2 Research Methodology and Data Sources
- 9.3 Glossary of Terms
- 9.4 Market Definitions
- 9.5 Contact Information



I would like to order

Product name: Primary Immunodeficiency Therapeutics Market Size, Trends, Analysis, and Outlook By

Disease (Antibody Deficiency, Cellular Immunodeficiency, Innate Immune Disorders, Others), By Product (Immunoglobulin Replacement Therapy, Stem Cell/Bone Marrow Transplantation, Antibiotic Therapy, Gene Therapy, Others), by Region, Country,

Segment, and Companies, 2024-2030

Product link: https://marketpublishers.com/r/PA5FE920DAD7EN.html

Price: US\$ 3,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/PA5FE920DAD7EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html



To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$